Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Do not super-excess me!

Rivella S.

Blood. 2012 May 31;119(22):5064-5. doi: 10.1182/blood-2012-04-418590. No abstract available.

2.

Integrated protein quality-control pathways regulate free α-globin in murine β-thalassemia.

Khandros E, Thom CS, D'Souza J, Weiss MJ.

Blood. 2012 May 31;119(22):5265-75. doi: 10.1182/blood-2011-12-397729.

3.

Selectively killing transformed cells through proteasome inhibition.

Grant S.

Cell Cycle. 2009 Oct 1;8(19):3074-5. No abstract available.

4.

Proteasome inhibition induces both antioxidant and hb f responses in sickle cell disease via the nrf2 pathway.

Pullarkat V, Meng Z, Tahara SM, Johnson CS, Kalra VK.

Hemoglobin. 2014;38(3):188-95. doi: 10.3109/03630269.2014.898651.

PMID:
24670032
5.

Novel proteasome inhibitors to overcome bortezomib resistance.

Ruschak AM, Slassi M, Kay LE, Schimmer AD.

J Natl Cancer Inst. 2011 Jul 6;103(13):1007-17. doi: 10.1093/jnci/djr160. Review.

PMID:
21606441
6.

Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells.

Azakir BA, Di Fulvio S, Kinter J, Sinnreich M.

J Biol Chem. 2012 Mar 23;287(13):10344-54. doi: 10.1074/jbc.M111.329078.

7.

Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells.

Sato A, Asano T, Ito K, Asano T.

Urology. 2012 Apr;79(4):966.e13-21. doi: 10.1016/j.urology.2011.11.033.

PMID:
22296623
8.

Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma.

Bonvini P, Zorzi E, Basso G, Rosolen A.

Leukemia. 2007 Apr;21(4):838-42. No abstract available.

PMID:
17268529
9.

Discovery and development of second-generation proteasome inhibitors.

Kirk CJ.

Semin Hematol. 2012 Jul;49(3):207-14. doi: 10.1053/j.seminhematol.2012.04.007. Review.

PMID:
22726543
10.

Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells.

Ju D, Xie Y.

Mol Med Rep. 2014 Nov;10(5):2609-12. doi: 10.3892/mmr.2014.2522.

PMID:
25174315
11.

Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib.

Gelman JS, Sironi J, Berezniuk I, Dasgupta S, Castro LM, Gozzo FC, Ferro ES, Fricker LD.

PLoS One. 2013;8(1):e53263. doi: 10.1371/journal.pone.0053263.

12.

Heat shock proteins and cancer therapy: the trail grows hotter!

Subjeck JR, Repasky EA.

Oncotarget. 2011 Jun;2(6):433-4. No abstract available.

13.

Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.

Zhu H, Zhang L, Dong F, Guo W, Wu S, Teraishi F, Davis JJ, Chiao PJ, Fang B.

Oncogene. 2005 Jul 21;24(31):4993-9.

14.

Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.

Sato A, Asano T, Ito K, Sumitomo M, Asano T.

BJU Int. 2012 Apr;109(8):1258-68. doi: 10.1111/j.1464-410X.2011.10533.x.

15.

Dissecting bortezomib: development, application, adverse effects and future direction.

Cao B, Li J, Mao X.

Curr Pharm Des. 2013;19(18):3190-200. Review.

PMID:
23151134
16.

When ubiquitin meets NF-κB: a trove for anti-cancer drug development.

Wu ZH, Shi Y.

Curr Pharm Des. 2013;19(18):3263-75. Review.

17.

Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.

Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, Fanourakis G, Tseleni-Balafouta S, Ain KB, Mitsiades N.

J Clin Endocrinol Metab. 2006 Oct;91(10):4013-21.

PMID:
16849420
18.

Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma.

Shapovalov Y, Benavidez D, Zuch D, Eliseev RA.

Int J Cancer. 2010 Jul 1;127(1):67-76. doi: 10.1002/ijc.25024.

19.

Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.

Altmann A, Markert A, Askoxylakis V, Schöning T, Jesenofsky R, Eisenhut M, Haberkorn U.

J Nucl Med. 2012 Nov;53(11):1764-71. doi: 10.2967/jnumed.111.101295.

20.

[Pharmacological and clinical profile of Bortezomib (Velcade)].

Fujii H, Kotobuki Y, Nomura S, Harada Y.

Nihon Yakurigaku Zasshi. 2007 Nov;130(5):421-9. Review. Japanese. No abstract available.

PMID:
18000359

Supplemental Content

Support Center